Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis
Top Cited Papers
Open Access
- 10 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 50 (3), 548-557
- https://doi.org/10.1007/s11239-020-02171-y
Abstract
In the recent outbreak of novel coronavirus infection worldwide, the risk of thrombosis and bleeding should be concerned. We aimed to observe the dynamic changes of D-dimer levels during disease progression to evaluate their value for thrombosis. In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed. The Padua prediction score is used to identify patients at high risk for venous thromboembolism (VTE). The results found that, on admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-dimer levels were higher in COVID-19 patients (P < 0.05). Besides, we found that in COVID-19 patients, D-dimer were related with markers of inflammation, especially with hsCRP (R = 0.426, P < 0.05). However, there was low correlation between VTE score and D-dimer levels (Spearman’s R = 0.264, P > 0.05) weakened the role of D-dimer in the prediction of thrombosis. After treatments, D-dimer levels decreased which was synchronous with hsCRP levels in patients with good clinical prognosis, but there were still some patients with anomalous increasing D-dimer levels after therapy. In conclusion, elevated baseline D-dimer levels are associated with inflammation but not with VTE score in COVID-19 patients, suggesting that it is unreasonable to judge whether anticoagulation is needed only according to D-dimer levels. However, the abnormal changes of D-dimer and inflammatory factors suggest that anticoagulant therapy might be needed.Keywords
This publication has 30 references indexed in Scilit:
- Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung InjurymBio, 2013
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trialEuropean Journal of Internal Medicine, 2012
- The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admissionJournal of Critical Care, 2011
- Coagulation and inflammation biomarkers may help predict the severity of community‐acquired pneumoniaRespirology, 2010
- Effectiveness of Managing Suspected Pulmonary Embolism Using an Algorithm Combining Clinical Probability, D-Dimer Testing, and Computed TomographyJAMA, 2006
- SARS: clinical features and diagnosisRespirology, 2003
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsisIntensive Care Medicine, 2002
- Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2000